Phaseline

Targets › ERGOSTEROL

ERGOSTEROL: drug programs, companies and trials

3 programs from 3 companies in 3 trials: 2 Phase 2, 1 Phase 4; Infectious disease, Oncology, Other; next expected readout Jun 2027.

Open in Phaseline: the race on ERGOSTEROL, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Copenhagen University Hospital, RigshospitaletFluconazole
Cytochrome P450 51 inhibitor
ERGOSTEROLPhase 4CystectomyJun 2027
National Cancer Institute (NCI)Itraconazole
Cytochrome P450 51 inhibitor
ERGOSTEROLPhase 2Barrett EsophagusAug 2030
AVVA PharmaceuticalsClotrimazole
Cytochrome P450 51 inhibitor
ERGOSTEROLPhase 2Candidal Vulvovaginitis (ICD-10 Code: B37.3)–

Conditions

Candidal Vulvovaginitis (ICD-10 Code: B37.3) (1) Barrett Esophagus (1) Cystectomy (1)

Modalities

small molecule (3)

Companies

AVVA Pharmaceuticals (1) National Cancer Institute (NCI) (1) Copenhagen University Hospital, Rigshospitalet (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.